Syntegon lifts H1 sales 7% on Pharma strength, confirms 2026 guidance

Syntegon reported first-half 2026 sales up 7% to EUR 883m, with adjusted EBITDA up 16% to EUR 148m and margin rising 130 basis points to 16.8%. Growth was driven by Pharma, where sales rose 14%, while the Food business, notably chocolate and bars packaging, was held back by cautious customer investment amid cost pressure. The company maintains its full-year 2026 guidance for profitable growth, backed by a record order backlog of EUR 1.3bn.

Why this mattersPharma and biotech demand is offsetting a slowdown in food-sector capex, underlining a widening divergence in machinery investment across end markets.

• H1 2026 sales rose 7% year on year to EUR 883m
• Adjusted EBITDA grew 16% to EUR 148m, margin up 130 basis points to 16.8%
• Order intake reached EUR 964m, book-to-bill ratio of 1.09, backlog at a record EUR 1.3bn
• Pharma segment sales grew 14% and remained the main growth driver, including gains in US biologics
• Food segment growth was limited, particularly in chocolate and bars, on cautious customer investment
• Company reaffirms guidance for continued profitable growth in 2026

Relevant to you? Yes No